Stockholm III trial

The Stockholm III trial is a randomised, multicentre trial, comparing different radiationtherapy courses in primary resectable rectal cancer.

Patients are randomised between one of the following arms:

  1. Preoperative radiotherapy 5 x 5 Gy with surgery within one week
  2. Preoperative radiotherapy 5 x 5 Gy with surgery after 4-8 weeks
  3. Preoperative radiotherapy 25 x 2 Gy with surgery after 4-8 weeks

Inclusion criteria:

Primary resectable, biopsy proven adenocarcinoma of the rectum, without signs of distant metastases where abdominal surgery is planned.

Primary Investigator

Anna Martling

Professor/senior physician

www.clinicaltrials.gov NCT00904813

Publikationer

Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.
Erlandsson J, Holm T, Pettersson D, et al
Lancet Oncol. 2017 Feb;18(3):336-46

Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer.
Pettersson D, Cedermark B, Holm T, Radu C, Påhlman L, Glimelius B, et al
Br J Surg 2010 Apr;97(4):580-7

Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial.
Pettersson D, Glimelius B, Iversen H, Johansson H, Holm T, Martling A
Br J Surg 2013 Jun;100(7):969-75

Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer.
Pettersson D, Lörinc E, Holm T, Iversen H, Cedermark B, Glimelius B, et al
Br J Surg 2015 Jul;102(8):972-8; discussion 978